Acute chest pain is a common yet challenging clinical presentation, often requiring prompt diagnosis and management. The etiology can range from benign musculoskeletal conditions to life-threatening cardiovascular diseases. This article outlines a comprehensive approach to diagnosing and managing acute chest pain.
The initial evaluation should include a detailed history and physical examination, focusing on risk factors, pain characteristics, and associated symptoms. Electrocardiography (ECG) and biomarker testing are essential for early diagnosis of acute coronary syndrome (ACS).
Beyond initial assessment, further diagnostic modalities may be required. Chest radiography can identify pulmonary and aortic conditions, while computed tomography (CT) angiography is effective for diagnosing pulmonary embolism or aortic dissection. Echocardiography can help evaluate myocardial function and pericardial diseases.
Management strategies should be tailored based on the underlying cause. For ACS, immediate reperfusion therapy is critical. Anticoagulation is the cornerstone of treatment for pulmonary embolism, while surgical intervention may be required for aortic dissection. Analgesia and anti-inflammatory medications are often sufficient for musculoskeletal pain.
Risk stratification tools, such as the HEART score, can guide clinical decision-making and disposition. Low-risk patients may be suitable for outpatient management, while high-risk patients require hospitalization and aggressive intervention.
Acute chest pain presents a diagnostic challenge due to its varied etiology. A comprehensive approach, incorporating history, physical examination, diagnostic testing, and risk stratification, is essential to ensure accurate diagnosis and appropriate management. Continuing education and adherence to clinical guidelines can further enhance patient outcomes.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation